NewslettersNeural Cell News Novartis Tafinlar + Mekinist Approved by FDA for Pediatric Patients with BRAF V600E Low-Grade Glioma, the Most Common Pediatric Brain Cancer By Jamie Kang - March 21, 2023 0 Novartis announced the US FDA granted approval for Tafinlar® + Mekinist® for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. [Novartis] Press Release